Sale

Methicillin-Resistant Staphylococcus Aureus Drugs Market by Agent Type, Route of Administration, Sales Channel - Global Forecast 2025-2030

Report
185 Pages
October 2024
Region: Global
360iResearch™
ID: 4968650

UP TO €681EUR$697USD£568GBP OFF until Dec 31^st 2024

The Methicillin-Resistant Staphylococcus Aureus Drugs Market grew from USD 2.09 billion in 2023 to USD 2.21 billion in 2024. It is expected to continue growing at a CAGR of 6.39%, reaching USD 3.22 billion by 2030.

Methicillin-Resistant Staphylococcus Aureus (MRSA) drugs are crucial in combating infections caused by the notoriously resistant MRSA bacteria, greatly limiting treatment options for patients. This field encompasses antibiotics specifically developed to target and eliminate the resilient strains of MRSA, with applications extending from hospital and community-acquired infections to post-surgical care and chronic wound management. The market is buoyed by the increasing prevalence of MRSA infections globally, compounded by the misuse and overuse of antibiotics that spur resistance, alongside a growing awareness and adoption of MRSA screening protocols in healthcare settings. Nevertheless, market growth is hampered by challenges such as the high cost of MRSA therapies and the complexity of obtaining regulatory approvals due to strict efficacy and safety standards. Key opportunities lie in the development of novel antibiotics and alternative therapies, such as bacteriophage treatments or antibody therapies, which hold the potential for circumventing traditional resistance mechanisms. Companies should also consider investing in rapid diagnostic technologies to improve early detection and treatment personalization, which could significantly enhance therapeutic outcomes and market reach. The dynamic nature of MRSA demands continuous R&D and innovation to stay ahead of emerging resistant strains. However, firms must navigate market limitations like reimbursement issues and competition from generic drugs, which pressurize pricing and profit margins. In addressing these challenges, strategic partnerships, government incentives, and an emphasis on sustainable antibiotic stewardship will be essential. The MRSA drugs market presents a compelling landscape for innovation, where the integration of cutting-edge biotechnologies and robust clinical research pathways can carve competitive advantages, ultimately driving business growth while combating a critical public health threat.

Understanding Market Dynamics in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

The Methicillin-Resistant Staphylococcus Aureus Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Growing prevalence of infections associated with methicillin-resistant staphylococcus aureus
- Rising investment in healthcare sector by private & public sector
Market Restraints
- Fluctuating cost of raw materials used in methicillin-resistant staphylococcus aureus drugs formulations
Market Opportunities
- Ongoing research & development activities to develop novel methicillin-resistant staphylococcus aureus drugs
- Increasing number of patent expiration of methicillin-resistant staphylococcus aureus drugs
Market Challenges
- Time consuming and strict regulatory approval processes

Exploring Porter’s Five Forces for the Methicillin-Resistant Staphylococcus Aureus Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Methicillin-Resistant Staphylococcus Aureus Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Methicillin-Resistant Staphylococcus Aureus Drugs Market

External macro-environmental factors deeply influence the performance of the Methicillin-Resistant Staphylococcus Aureus Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

The Methicillin-Resistant Staphylococcus Aureus Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

The Methicillin-Resistant Staphylococcus Aureus Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

The Methicillin-Resistant Staphylococcus Aureus Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Methicillin-Resistant Staphylococcus Aureus Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Aridis Pharmaceuticals Inc., Armata Pharmaceuticals, Inc., AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bausch Health Companies Inc., Baxter International Inc., Becton, Dickinson and Company, Cardinal Health, Inc., Cumberland Pharmaceuticals Inc., Debiopharm SA, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, GlaxoSmithKline PLC, Innovation Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Nabriva Therapeutics GMBH, Novartis AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., R-Biopharm AG, Shionogi Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries ltd, and Theravance Biopharma, Inc..

Market Segmentation & Coverage

This research report categorizes the Methicillin-Resistant Staphylococcus Aureus Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Agent Type
- Ceftaroline
- Daptomycin
- Linezolid
- Telavancin
- Vancomycin
Route of Administration
- Oral
- Parenteral
Sales Channel
- Offline
  - Hospitals Pharmacies
  - Retail Pharmacies
- Online

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of infections associated with methicillin-resistant staphylococcus aureus
5.1.1.2. Rising investment in healthcare sector by private & public sector
5.1.2. Restraints
5.1.2.1. Fluctuating cost of raw materials used in methicillin-resistant staphylococcus aureus drugs formulations
5.1.3. Opportunities
5.1.3.1. Ongoing research & development activities to develop novel methicillin-resistant staphylococcus aureus drugs
5.1.3.2. Increasing number of patent expiration of methicillin-resistant staphylococcus aureus drugs
5.1.4. Challenges
5.1.4.1. Time consuming and strict regulatory approval processes
5.2. Market Segmentation Analysis
5.2.1. Agent Type: Evolving adoption of daptomycin for effective treatment of MRSA
5.2.2. Sales Channel: Expanding preference towards online channels due to easy access
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Agent Type

6.1. Introduction
6.2. Ceftaroline
6.3. Daptomycin
6.4. Linezolid
6.5. Telavancin
6.6. Vancomycin

7. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Route of Administration

7.1. Introduction
7.2. Oral
7.3. Parenteral

8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Sales Channel

8.1. Introduction
8.2. Offline
8.3. Online

9. Americas Methicillin-Resistant Staphylococcus Aureus Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. UK Government's Strategic Investment in Global AMR Surveillance, Strengthening Health Systems Across Asia and Africa
12.3.2. Basilea Seeks FDA Approval for New MRSA-Fighting Antibiotic Ceftobiprole
12.3.3. BARDA's Strategic Funding Initiative for Melinta Therapeutics to Enhance Pediatric Antibiotic Access
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio

List of Figures

FIGURE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET DYNAMICS
FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
FIGURE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TELAVANCIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TELAVANCIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 45. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 46. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 49. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 50. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 51. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 52. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 53. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 54. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 55. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 56. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 57. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 58. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 59. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 60. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 61. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 62. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 63. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 64. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 65. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 66. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 67. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 68. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 69. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 70. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 71. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 72. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 73. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 74. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 75. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 76. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 77. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 78. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 79. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 80. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 81. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 82. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 83. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 84. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 85. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 86. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 87. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 88. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 90. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 92. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 94. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 96. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 98. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 99. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 100. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 101. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 102. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 103. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 104. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 105. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 106. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 107. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 108. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 109. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 110. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 111. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 112. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 113. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 114. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 115. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 116. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 117. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 118. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 119. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 120. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 121. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 122. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 123. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 124. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 125. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 126. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 127. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 128. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 129. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 130. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 131. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 132. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 133. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 134. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 135. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 136. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 137. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 138. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 139. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 140. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 141. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 142. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 143. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 144. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 145. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 146. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 147. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 148. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 149. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 150. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 151. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 152. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 153. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 154. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 155. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 156. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 157. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 158. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 159. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 160. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 161. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 162. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 163. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 164. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 165. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 166. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 167. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 168. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 169. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 170. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 171. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 172. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 173. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 174. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 175. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 176. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 177. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 178. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 179. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 180. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 181. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 182. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 183. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 184. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 185. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 186. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 187. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 188. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 189. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 190. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 191. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 192. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 193. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 194. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 205. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 206. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 207. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 208. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 209. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 210. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 211. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 212. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 213. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 214. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 215. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 216. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 217. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 218. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 219. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 220. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 221. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 222. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 223. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 224. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 225. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 226. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 227. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 228. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 229. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 230. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 231. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 232. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 233. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 234. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 235. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 236. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 237. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 238. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 239. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 240. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 241. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 242. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 243. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 244. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 245. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 246. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 247. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 248. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 249. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 250. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 251. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 252. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 253. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 254. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 255. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 256. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 257. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 258. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 259. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 260. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 261. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
TABLE 262. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
TABLE 263. NETHERLANDS METHICILL

Companies Mentioned

The leading players in the Methicillin-Resistant Staphylococcus Aureus Drugs market, which are profiled in this report, include:

AbbVie Inc.
Aridis Pharmaceuticals Inc.
Armata Pharmaceuticals, Inc.
AstraZeneca PLC
Basilea Pharmaceutica Ltd.
Bausch Health Companies Inc.
Baxter International Inc.
Becton, Dickinson and Company
Cardinal Health, Inc.
Cumberland Pharmaceuticals Inc.
Debiopharm SA
Dr. Reddy's Laboratories Ltd.
F. Hoffmann-La Roche Ltd.
Fresenius Kabi AG
GlaxoSmithKline PLC
Innovation Pharmaceuticals Inc.
Johnson & Johnson Services, Inc.
Lupin Limited
Merck & Co., Inc.
Nabriva Therapeutics GMBH
Novartis AG
Paratek Pharmaceuticals, Inc.
Pfizer Inc.
R-Biopharm AG
Shionogi Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries ltd
Theravance Biopharma, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	185
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 2.21 Billion
Forecasted Market Value ( USD ) by 2030	$ 3.22 Billion
Compound Annual Growth Rate	6.3%
Regions Covered	Global
No. of Companies Mentioned	28

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3464EUR$3,545USD£2,892GBP €3849EUR$3,939USD£3,213GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6128EUR$6,272USD£5,116GBP €6809EUR$6,969USD£5,684GBP

Understanding Market Dynamics in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

Exploring Porter’s Five Forces for the Methicillin-Resistant Staphylococcus Aureus Drugs Market

Applying PESTLE Analysis to the Methicillin-Resistant Staphylococcus Aureus Drugs Market

Analyzing Market Share in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

Strategic Recommendations for Success in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2024

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insight, Epidemiology and Market Forecast - 2034

Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2024

Methicillin-resistant Staphylococcus Aureus Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Global Clinical Trials Review, 2024

About the MRSA Drug Market